- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07947069
Nebulized Plus Intravenous Versus Intravenous Furosemide in Pulmonary Edema
Effectiveness of Nebulized Plus Intravenous Furosemide Versus Intravenous Furosemide in Treating Pulmonary Edema: A Randomized Controlled Trial
This randomized controlled trial compares intravenous furosemide alone with intravenous plus nebulized furosemide in adults with acute pulmonary edema. The main outcome is the change in peripheral oxygen saturation (SpO2) from baseline, and the secondary outcome is the change in dyspnea severity on a 0-10 visual analogue scale. The trial will test whether adding nebulized furosemide to standard intravenous furosemide gives additional benefit.
연구 개요
상세 설명
Pulmonary edema is a medical emergency in which fluid collects in the alveolar spaces, impairing gas exchange and causing respiratory distress. Intravenous furosemide is the mainstay of treatment but may cause hypotension, electrolyte imbalance and renal dysfunction. Nebulized furosemide delivers the drug directly to the lungs and may improve dyspnea and oxygenation through local effects. Most available studies have tested nebulized furosemide as an alternative to intravenous therapy rather than as an adjunct, so it remains unclear whether the combination offers added benefit over intravenous furosemide alone.
Methods: A randomized controlled trial will be conducted in the Department of Medicine, Federal Government Polyclinic Hospital, Islamabad, over 6 months after ethical approval, using non-probability consecutive sampling. A total of 130 patients (65 per group) will be enrolled. Sample size was calculated with the WHO formula for two means (alpha 0.05, power 80%, SD 1.5, expected difference 0.7) based on Barzegari et al. (2021). After written informed consent, baseline demographics, vital signs, SpO2 and dyspnea VAS score will be recorded. All patients will receive standard initial care with oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg. Patients will be randomized 1:1 using a computer-generated sequence with sequentially numbered, opaque, sealed envelopes. Group A will receive intravenous furosemide 1 mg/kg plus nebulized furosemide 40 mg in 4 ml 0.9% saline, and Group B will receive intravenous furosemide 1 mg/kg alone. SpO2 and dyspnea VAS will be recorded at baseline and at 30, 60 and 120 minutes after intervention.
Statistical analysis: Data will be analyzed in SPSS version 23. Continuous variables will be presented as mean and standard deviation. Between-group comparison of change from baseline in SpO2 and VAS will be done with the independent samples t-test, or the Mann-Whitney U test for non-normal data. Baseline SpO2, baseline dyspnea score, oxygen flow rate, use of nitrates or morphine and underlying cardiac function will be recorded as potential confounders. A p-value below 0.05 will be considered significant.
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: Tausif Khan
- 전화번호: +923110920949
- 이메일: mtausifkhan1999@gmail.com
연구 장소
-
-
Islamabad
-
Islamabad, Islamabad, 파키스탄, 44000
- Department of Medicine, Federal Government Polyclinic Hospital
-
수석 연구원:
- Tausif Khan
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Adults aged 18 to 94 years
- Acute shortness of breath within the past 6 hours
- Clinical features of pulmonary edema (tachypnea, use of accessory muscles, crepitations, wheeze, gallop rhythm) with chest X-ray showing bilateral pulmonary infiltrates consistent with pulmonary edema, with or without cardiomegaly, pulmonary vascular congestion, Kerley B lines or pleural effusion
Exclusion Criteria:
- Cardiogenic shock or systolic blood pressure below 90 mm Hg
- Need for intubation, cardiac arrhythmia or liver failure
- COPD or asthma exacerbation
- End-stage renal disease on dialysis
- Allergy to furosemide
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Group A: IV plus nebulized furosemide
Intravenous furosemide 1 mg/kg slow push over 5 minutes plus nebulized furosemide 40 mg diluted in 4 ml 0.9% saline over 15 minutes, in addition to standard initial care (oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg). |
Furosemide 40 mg diluted in 4 ml 0.9% saline given by jet nebulizer over 15 minutes.
다른 이름들:
Furosemide 1 mg/kg given as a slow intravenous push over 5 minutes.
다른 이름들:
|
|
활성 비교기: Group B: IV furosemide
Intravenous furosemide 1 mg/kg slow push over 5 minutes, in addition to standard initial care (oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg). |
Furosemide 1 mg/kg given as a slow intravenous push over 5 minutes.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in peripheral oxygen saturation (SpO2)
기간: Baseline, 30, 60 and 120 minutes after intervention (primary comparison at 60 minutes)
|
SpO2 (%) measured with a calibrated pulse oximeter; change from baseline will be compared between groups. |
Baseline, 30, 60 and 120 minutes after intervention (primary comparison at 60 minutes)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in dyspnea severity on Visual Analogue Scale (VAS)
기간: Baseline, 30, 60 and 120 minutes after intervention
|
Patient-rated breathlessness on a 0-10 VAS (0 = no breathlessness, 10 = worst breathlessness); change from baseline will be compared between groups. |
Baseline, 30, 60 and 120 minutes after intervention
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Tausif Khan, MBBS, FCPS Trainee, Federal Government Polyclinic Hospital, Islamabad
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- FGPC-PGMI-MED-2026-PE01
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .